Evofem Biosciences to Report Fourth Quarter and Year-End 2021 Results and Provide Corporate Update on Thursday, March 3, 2022

Rhea-AI Summary

Evofem Biosciences, Inc. (NASDAQ: EVFM) will host a webcast and conference call on March 3, 2022, at 4:30 p.m. ET to discuss its financial results and business highlights for Q4 and the year ended December 31, 2021. Interested parties can access the live and archived webcast through the company's investor room. The conference call can be joined via phone, with a replay available for 24 hours post-call. Evofem is focused on developing innovative women's sexual and reproductive health products, including the FDA-approved contraceptive gel, Phexxi®.

SAN DIEGO, Feb. 17, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the fourth quarter and year ended December 31, 2021 on Thursday, March 3, 2022 at 4:30 p.m. ET (1:30 p.m. PT).

The webcast (live and archived) and related slide presentation can be accessed through https://evofem.investorroom.com/2021Q4YEResults or directly at https://edge.media-server.com/mmc/p/vdypceqy. Please connect to the webcast at least 15 minutes prior to the start of the call to download any software that may be required.

If participating by phone, please dial in approximately 15 minutes prior to the start of the call using (866) 503-5561 (U.S. toll-free) or (253) 336-2965, and referring to conference ID 9976995.

A telephone replay will be available for 24 hours after the call at (855) 859-2056 (U.S.) or (404) 537-3406 (International), conference ID 9976995.

About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (chlamydia and gonorrhea). The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com and evofem.com.

Phexxi^® is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-to-report-fourth-quarter-and-year-end-2021-results-and-provide-corporate-update-on-thursday-march-3-2022-301484595.html

SOURCE Evofem Biosciences, Inc.

FAQ

What date will Evofem Biosciences announce its Q4 2021 financial results?

Evofem Biosciences will announce its Q4 2021 financial results on March 3, 2022.

What time is the Evofem Biosciences conference call scheduled?

The Evofem Biosciences conference call is scheduled for 4:30 p.m. ET on March 3, 2022.

How can I access the Evofem Biosciences Q4 earnings call?

You can access the Evofem Biosciences Q4 earnings call via their investor room at https://evofem.investorroom.com/2021Q4YEResults.

Is there a replay available for the Evofem Biosciences earnings call?

Yes, a telephone replay of the Evofem Biosciences earnings call will be available for 24 hours after the call.

What is the primary product of Evofem Biosciences?

Evofem Biosciences' primary product is Phexxi®, a hormone-free contraceptive gel.